In a randomized clinical trial published in the Journal of Internal Medicine, ingesting capsules containing fecal microbes from healthy donors helped treat symptoms of insomnia.
One month after treatment, participants receiving fecal microbiota capsules showed significantly higher sleep efficiency and reduced wake after sleep onset, as measured by overnight polysomnography. Patient questionnaires also showed that sleep quality scores improved from 2 to 6 months in the intervention group compared with the placebo group.
"Our findings provide clinical evidence that targeting the gut microbiota may offer a promising new therapeutic strategy for chronic insomnia disorder,” said co–corresponding author Yanping Bao, PhD, of Peking University, in Beijing. “This work also strengthens our understanding of the gut–brain axis as an important regulator of human sleep.”
URL: https://onlinelibrary.wiley.com/doi/10.1111/joim.70137
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com.
About the Journal
Journal of Internal Medicine is a peer-reviewed scientific journal that publishes original clinical work from bench to bedside covering a broad field of its subspecialties. JIM features original articles, reviews and clinical updates.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.